<DOC>
	<DOCNO>NCT00327444</DOCNO>
	<brief_summary>This study design characterize effect aflibercept participant advance chemoresistant ovarian cancer . Primary objective : Compare effect aflibercept ( ziv-aflibercept , AVE0005 , VEGF trap , ZALTRAPÂ® ) placebo treatment repeat paracentesis symptomatic malignant ascites participant advanced ovarian cancer Secondary objective : Safety , tolerability , paracentesis-related parameter , participant-reported outcome .</brief_summary>
	<brief_title>Study Effect Intravenous AVE0005 ( VEGF Trap ) Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites</brief_title>
	<detailed_description>The study include : - A Thirty ( 30 ) -day screen phase - The double blind treatment period minimum 60 day . Day 1 double-blind treatment period define date qualify paracentesis ( ie , withdrawal &gt; = 1 Liter ascitic fluid ) . Participants randomize adequate recovery qualify paracentesis ( The first dose administer Day 1 Day 2 ) . - The optional open-label extension ( treatment discontinuation criterion meet ) - A posttreatment follow-up phase last 60 day . Criteria discontinuation include : 1 . Participant legally authorize representative request discontinuation 2 . In Investigator 's opinion , continuation treatment would detrimental participant 's well , disease progression , unacceptable toxicity , noncompliance , logistical consideration 3 . Sponsor request 4 . Intercurrent illness prevent administration investigational product ( IP ) 5 . More 2 IP dose reduction 6 . Unacceptable adverse event ( AE ) manageable symptomatic therapy , dose delay , dose modification 7 . Arterial thromboembolic event , include cerebrovascular accident , myocardial infarction , transient ischemic attack , new onset worsen preexist angina 8 . Radiographic evidence intestinal obstruction ( example , dilate loops bowel accompany air-fluid level ) gastrointestinal perforation ( example , presence extraluminal gas ) require surgical intervention</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<criteria>Participants meet follow criterion eligible participate study . Advanced ovarian epithelial cancer , treat paracentesis Platinumresistant , topotecanresistant and/or liposomal doxorubicinresistant disease ; Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 . Pseudomyxoma peritonei peritoneal mesothelioma ; Transudative ascites ; Peritoneovenous shunt place malignant ascites management ; Recent ( &lt; 6 month ) cardiovascular event ( pulmonary embolus , myocardial infarction , stroke ) gastrointestinal disease ( ulcer , hepatic cirrhosis ) ; Known brain metastasis ; Uncontrolled hypertension ; Recent treatment chemotherapy , surgery radiotherapy ; Prior treatment VEGF VEGFR inhibitor . The information intend contain consideration relevant participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Ovarian neoplasm</keyword>
	<keyword>Ascites</keyword>
	<keyword>Angiogenesis inhibitor</keyword>
	<keyword>Vascular Endothelial Growth Factor A</keyword>
	<keyword>Recombinant fusion protein</keyword>
</DOC>